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81* A double-blind, multinational, randomized, placebo-controlled
trial evaluating aztreonam for inhalation solution (AZLI) in patients
with cystic ﬁbrosis (CF), mild lung disease and P. aeruginosa (PA)
C. Wainwright1, C. Nakamura2, D. Geller3, A.B. Montgomery4. 1Royal Children’s
Hospital, Herston, QLD, Australia; 2Childrens Lung Specialists, Las Vegas, NV,
United States; 3Nemours Children’s Clinic, Orlando, FL, United States; 4Gilead
Sciences, Seattle, WA, United States
Patients (6 years, FEV1 7gt;75% predicted, PA positive within 3 months prior to
or at screening) received AZLI (n = 76) or placebo (n = 81) TID for 28 days, with
14 days of followup. Baseline FEV1 was 95.1% predicted. Statistically signiﬁcant
AZLI-placebo treatment differences were not observed at Day 28 for the primary
efﬁcacy endpoint, CFQ-R Respiratory Symptoms scores (RSS), but were observed
for the secondary endpoints of PA density and FEV1 % predicted (Table). At Day 28,
the percentage of PA-positive patients decreased 20% in the AZLI group while
remaining similar to baseline in the placebo group. The most commonly-reported
adverse event was cough (AZLI vs. placebo: 35 [46%] vs. 31 [38%]).
Patients with baseline FEV1 <90% predicted had larger AZLI-placebo treatment
differences for CFQ-R RSS and FEV1 % predicted than did patients with baseline
FEV1 % predicted 90% (Table).
Mean AZLI–placebo treatment differences at day 28
Overall FEV1 at baseline
(N= 157) <90% Predicted
(N= 62)
90% Predicted
(N= 95)
CFQ-R RSS (points) 1.8; p = 0.44 6.7; p = 0.07 −1.4; p = 0.66
PA density (log10 CFUs
in sputum)
−1.2; p = 0.02 −0.7; p = 0.31 −1.6; p = 0.04
FEV1 % Predicted
(relative % change)
2.7%; p = 0.02 4.8%; p = 0.03 1.4%; p = 0.30
Treatment of patients with mild CF lung disease with 75mg AZLI TID for 28 days
was well-tolerated. AZLI-treated patients preserved lung function and suppressed
PA compared with placebo. Overall effects on respiratory symptoms were modest,
perhaps due to high baseline FEV1 % predicted (95.1%) and CFQ-R RSS (72.0).
82* Safety and efﬁcacy of tobramycin inhalation powder (TIP) in
treating CF patients infected with Pseudomonas aeruginosa (Pa)
M. Konstan1, P.A. Flume2, F. Brockhaus3, G. Angyalosi3, E. He4, D. Geller5.
1Rainbow Babies and Children’s Hospital, Cleveland, OH, United States; 2Medical
University of South Carolina, Charleston, SC, United States; 3Novartis, Basel,
Switzerland; 4Novartis, East Hanover, NJ, United States; 5Nemours Children’s
Clinic, Orlando, FL, United States
Objective: To evaluate the safety and efﬁcacy of TIP compared to TOBI in
CF patients with Pa infection.
Methods: Open-label, multicenter, active comparator study, comprising 3 treatment
cycles (28 days on-drug followed by 28 days off-drug) in Pa-infected CF patients age
6 yrs old randomised 3:2 to TIP (112mg tobramycin/4 capsules) or TOBI (300mg
tobramycin/5mL) twice daily. Safety and efﬁcacy outcomes were evaluated.
Results: 517 patients (TIP=308, TOBI=209; 55.3% male; mean age 25.6 y, mean
baseline FEV1 % predicted 53.0) were randomised; 88% of patients experienced
AEs, which were mostly mild or moderate in severity. Treatment-related AEs more
commonly found in the TIP group were cough (25.3% vs 4.3%), dysgeusia (3.9%
vs 0.5%) and dysphonia (12.7% vs 3.3%). A slightly greater increase in FEV1 %
predicted from baseline to end of Cycle 3 was observed with TIP (5.8) compared
to TOBI (4.7) [LS mean difference: 1.1; lower bound of 1-sided 85% CI=-0.67].
Mean change in sputum density of Pa biotypes (log10CFU/g) was comparable
within treatments across the 3 cycles and greater with TIP compared to TOBI.
The distribution of tobramycin MIC of Pa isolates was relatively consistent over
the course of study. Anti-Pseudomonal antibiotics other than inhaled tobramycin
were more commonly used in the TIP group, but for a shorter average time than in
the TOBI group.
Conclusion: Overall TIP safety proﬁle was similar to TOBI, except certain local
tolerability side effects which may be related to the relatively high amount of powder
with TIP. TIP had numerically slightly better efﬁcacy (FEV1 and Pa density) than
TOBI.
83 Treatment convenience and satisfaction of tobramycin inhalation
powder (TIP) versus TOBI in cystic ﬁbrosis (CF) patients
D.E. Geller1, P.A. Flume2, F. Brockhaus3, J. Zhang4, G. Angyalosi3, E. He4,
M. Konstan5. 1Nemours Children’s Clinic, Orlando, FL, United States; 2Medical
University of South Carolina, Charleston, SC, United States; 3Novartis, Basel,
Switzerland; 4Novartis, East Hanover, NJ, United States; 5Rainbow Babies and
Children’s Hospital, Cleveland, OH, United States
Objective: Nebulised therapy places a time burden on CF patients. We evaluated the
convenience and satisfaction with a new formulation of tobramycin (TIP) compared
with TOBI.
Methods: Open-label, multicenter, active comparator study in CF patients age 6
years with Pseudomonas aeruginosa (Pa) infection. Patients were randomised (3:2)
to TIP (112mg tobramycin/4 capsules) administered via dry powder inhaler or
TOBI (300mg tobramycin/5mL) administered via PARI LC Plus nebuliser twice
daily for 3 treatment cycles (28 days on-therapy followed by 28 days off-therapy).
Self-reported satisfaction was measured using the modiﬁed Treatment Satisfaction
Questionnaire for Medication (TSQM) factored into four domains: Effectiveness,
Side Effects, Convenience, and Global Satisfaction.
Results: 517 patients (TIP = 308, TOBI = 209; 55.3% male; mean age: 25.6 y,
mean baseline FEV1 %predicted 53.0) were randomised. Treatment satisfaction
was signiﬁcantly higher for TIP than TOBI at all visits for the effectiveness
(P < 0.0001), convenience (P < 0.0001), and global satisfaction (P = 0.0018). There
was no difference in side effects ratings between groups nor were there any changes
in satisfaction scores within treatment groups over time. The overall administration
time for TIP (median: 5.6 min) was 14min less than TOBI (19.7min) supporting
the results of TSQM regarding convenience and global satisfaction.
Conclusion: CF patients rated TIP as more convenient and satisfying than TOBI
for treating Pa infections, consistent with the shorter treatment time for TIP.
84 In-vivo data support equivalent therapeutic efﬁcacy of a new
tobramycin inhalation solution (150mg/1.5ml) administered by the
eFlow® electronic nebuliser compared to TOBI® in the PARI LC PLUS®
M. Keller1, A.L. Coates2, M. Griese3, O. Denk1, J. Schierholz1, M. Knoch1. 1PARI
Pharma GmbH, Aerosol Research Insitute, Graefelﬁng, Germany; 2Hospital for Sick
Children, Toronto, ON, Canada; 3Haunersches Children Hospital, Munich, Germany
Aims: Two clinical studies were conducted to demonstrate equivalent lung deposition
and safety in CF patients for a new tobramycin inhalation solution 150mg/1.5ml
(Tobramycin PARI) delivered by an investigational eFlow® electronic nebuliser in
comparison to TOBI® (300mg/5ml) administered by the PARI LC PLUS® breath
enhanced jet nebulizer powered by a PARI BOY® N compressor.
Methods: Lung deposition of two 99mTC-DTPA labelled tobramycin solutions was
investigated in a cross over study design. The inhalation of TOBI® via the PARI LC
PLUS® and Tobramycin PARI via an investigational eFlow nebulizer was studied in 16
CF patients (8 children and adults, each). Above medications were inhaled twice daily
in a second safety study, conducted in 76 CF patients (38 adults and children, each)
in a parallel design for 28 days. After 7 days, Tobramycin was assessed from sputum,
and Cmax, AUC from blood plasma.
Results: See the table; all results are mean values.
Comparison of TOBI and Tobramycin PARI
Group Lung deposition [mg] Sputum concentration [mg/L] Cmax [mg/L]
TOBI Tobramycin
PARI
TOBI Tobramycin
PARI
TOBI Tobramycin
PARI
All patients 45.4 46.0 2.27 2.59 1.65 1.29
Adults 46.8 45.6 2.65 2.67 1.81 1.21
Children 44.1 46.4 1.99 2.50 1.52 1.36
Conclusions: No statistically signiﬁcant differences were found regarding lung depo-
sition and sputum concentration being efﬁcacy parameters, but signiﬁcant differences
regarding AUC (p< 0.005 to p< 0.001) and Cmax (p = 0.02 and p< 0.001) being a
safety parameter. Inhalation time for Tobramycin PARI by an investigational eFlow®
was signiﬁcantly (p< 0.0001) shorter (4.6 vs. 16.1min) vs. TOBI®/LC PLUS® and
may help to improve patients’ quality of life and drug adherence.
